Kaye Spratt

Health Technology

Consumer Services

Profile

Kaye Spratt worked as the Director of Preclinical & Quality Control at Sangamo Therapeutics, Inc. from 1997 to 2015.
She also worked as a Senior Scientist at Somatix Therapy Corp.
and as the Vice President of Regulatory & Quality Assurance at Abeona Therapeutics, Inc. Dr. Spratt received her undergraduate degree from Langston University and her doctorate degree from Meharry Medical College.

Former positions of Kaye Spratt

Companies	Position	End
SANGAMO THERAPEUTICS, INC.	Corporate Officer/Principal	2014-12-31
Somatix Therapy Corp. Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA	Corporate Officer/Principal	-
ABEONA THERAPEUTICS INC.	General Counsel	-

See the detail of Kaye Spratt's experience

Training of Kaye Spratt

Meharry Medical College	Doctorate Degree
Langston University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kaye Spratt's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ABEONA THERAPEUTICS INC.	Health Technology
SANGAMO THERAPEUTICS, INC.	Health Technology

Private companies	1
Somatix Therapy Corp. Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA	Health Technology